Breast cancer: The upgraded role of HER-3 and HER-4

被引：52

作者：

Karamouzis, Michalis V.

Badra, Filitsa A.

Papavassiliou, Athanasios G.

机构：

[1] Univ Athens, Sch Med, Dept Biol Chem, GR-11527 Athens, Greece

[2] Thriass Gen Hosp, Dept Radiol, Athens, Greece

来源：

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY | 2007年 / 39卷 / 05期

关键词：

breast cancer; ErbB receptors; HER-3; HER-4;

D O I：

10.1016/j.biocel.2006.11.017

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Breast cancer is the most common cancer in women and the ErbB receptor family holds crucial role in its pathogenesis. Among them, epidermal growth factor receptor and HER-2 are the most studied members and their overexpression has been associated with aggressive clinical behaviour. These data were further strengthened by the clinical success of trastuzumab, a monoclonal antibody against HER-2 in breast cancer patients with HER-2 overexpression and/or amplification. However, trastuzumab failure in some patients may partly be attributed to co-expression of other ErbB receptors. Herein, we provide updated views regarding the role of HER-3 and HER-4 in breast cancer. Accumulated evidence implies that these receptors should be considered more than heterodimerisation partners. Their expression profile might be useful in predicting responsiveness to current treatment options, while new strategies targeting their ligands and downstream effectors are being developed. (C) 2006 Elsevier Ltd. All rights reserved.

引用

页码：851 / 856

页数：6

共 23 条

[11] Neuregulins 1-4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast
Marshall, Catherine
Blackburn, Edith
Clark, Mellissa
Humphreys, Steven
Gullick, William J.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 96 (02) : 163 - 168
[12] Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemo sensitivity effect in the absence of Her-2 overexpression
Menendez, Javier A.
Mehmi, Inderjit
Lupu, Ruth
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) : 3735 - 3746
[13] Oncogenic growth factor receptors: implications for signal transduction therapy
Mosesson, Y
Yarden, Y
[J]. SEMINARS IN CANCER BIOLOGY, 2004, 14 (04) : 262 - 270
[14] Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1
Muraoka-Cook, Rebecca S.
Caskey, Laura S.
Sandahl, Melissa A.
Hunter, Debra M.
Husted, Carty
Strunk, Karen E.
Sartor, Carolyn I.
Rearick, William A., Jr.
McCall, Wesley
Sgagias, Magdalene K.
Cowan, Kenneth H.
Earp, H. Shelton, III
[J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (17) : 6412 - 6424
[15] The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
Naresh, Anjali
Long, Weiwen
Vidal, Gregory A.
Wimley, William C.
Marrero, Luis
Sartor, Carolyn I.
Tovey, Sian
Cooke, Timothy G.
Bartlett, John M. S.
Jones, Frank E.
[J]. CANCER RESEARCH, 2006, 66 (12) : 6412 - 6420
[16] Lapatinib: A novel dual tyrosine kinase inhibitor with activity in solid tumors
Nelson, MH
Dolder, CR
[J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (02) : 261 - 269
[17] ROY Y, 2006, SEMINARS ONCOLOGY S9, V33, pS3
[18] TANOS B, 2006, J BIOL CHEM
[19] Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer
Tsai, MS
Shamon-Taylor, LA
Mehmi, I
Tang, CK
Lupu, R
[J]. ONCOGENE, 2003, 22 (05) : 761 - 768
[20] Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival
Wiseman, SM
Makretsov, N
Nielsen, TO
Gilks, B
Yorida, E
Cheang, M
Turbin, D
Gelmon, K
Huntsman, DG
[J]. CANCER, 2005, 103 (09) : 1770 - 1777

← 1 2 3 →